Valneva SE
PAR:VLA

Watchlist Manager
Valneva SE Logo
Valneva SE
PAR:VLA
Watchlist
Price: 2.05 EUR 0.49% Market Closed
Market Cap: 332.9m EUR
Have any thoughts about
Valneva SE?
Write Note

Valneva SE
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Valneva SE
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Valneva SE
PAR:VLA
Total Receivables
€30.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Nanobiotix SA
PAR:NANO
Total Receivables
€9.5m
CAGR 3-Years
15%
CAGR 5-Years
6%
CAGR 10-Years
15%
G
Genfit SA
PAR:GNFT
Total Receivables
€71m
CAGR 3-Years
72%
CAGR 5-Years
30%
CAGR 10-Years
44%
Inventiva SA
PAR:IVA
Total Receivables
€11m
CAGR 3-Years
25%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Total Receivables
€31.6m
CAGR 3-Years
-17%
CAGR 5-Years
12%
CAGR 10-Years
14%
OSE Immunotherapeutics SA
PAR:OSE
Total Receivables
€7.6m
CAGR 3-Years
-13%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
No Stocks Found

Valneva SE
Glance View

Market Cap
332.9m EUR
Industry
Biotechnology

Valneva SE is a biotech company. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 722 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

VLA Intrinsic Value
6.24 EUR
Undervaluation 67%
Intrinsic Value
Price

See Also

What is Valneva SE's Total Receivables?
Total Receivables
30.5m EUR

Based on the financial report for Sep 30, 2024, Valneva SE's Total Receivables amounts to 30.5m EUR.

What is Valneva SE's Total Receivables growth rate?
Total Receivables CAGR 1Y
-31%

Over the last year, the Total Receivables growth was -31%.

Back to Top